Ralliant (NYSE:RAL) Sets New 12-Month High After Better-Than-Expected Earnings

Ralliant Corporation (NYSE:RAL)’s share price hit a new 52-week high on Wednesday following a better than expected earnings announcement. The company traded as high as $56.20 and last traded at $56.1470, with a volume of 28082 shares trading hands. The stock had previously closed at $54.73.

The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. Ralliant’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Friday. Royal Bank Of Canada reduced their price objective on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday. Oppenheimer decreased their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Friday. Citigroup cut their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Barclays lifted their price target on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Ralliant currently has an average rating of “Moderate Buy” and an average price target of $51.30.

Institutional Investors Weigh In On Ralliant

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Ralliant by 10.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after buying an additional 1,415,327 shares in the last quarter. Dodge & Cox bought a new stake in Ralliant in the second quarter worth about $523,571,000. Viking Global Investors LP acquired a new stake in Ralliant in the 2nd quarter valued at about $257,200,000. State Street Corp bought a new position in shares of Ralliant during the 2nd quarter valued at about $213,096,000. Finally, Flossbach Von Storch SE grew its stake in shares of Ralliant by 1.7% in the 3rd quarter. Flossbach Von Storch SE now owns 4,152,866 shares of the company’s stock worth $181,605,000 after purchasing an additional 67,963 shares during the last quarter.

Ralliant Price Performance

The firm has a market capitalization of $4.46 billion and a P/E ratio of 31.10. The business’s fifty day moving average is $51.52 and its 200 day moving average is $46.72. The company has a current ratio of 0.84, a quick ratio of 1.03 and a debt-to-equity ratio of 0.38.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.